Crisil ESG Ratings assigns 'Crisil ESG 61' (Strong) rating based on FY 2025-26 data
Crisil ESG Ratings has assigned Aarti Drugs an ESG rating of 'Crisil ESG 61' (Strong), based on data pertaining to FY 2025-26.
- ESG Rating Assigned
- 'Crisil ESG 61' (Strong)
- Rating Basis Period
- FY 2025-26
- Report Received Date
- October 7, 2026
The disclosure in short
- Aarti Drugs has informed BSE and NSE that Crisil ESG Ratings & Analytic Limited, described as a SEBI registered Category-1 ESG Rating Provider, has assigned the company an ESG rating of 'Crisil ESG 61' (Strong).
- The rating is based on data pertaining to FY 2025-26.
- The report was received by the company on October 7, 2026; the intimation to the exchanges is dated October 8, 2026.
- The company states that it has not engaged Crisil ESG Ratings for the rating, and that Crisil prepared the report independently on the basis of company data available in the public domain.
What an ESG rating is
ESG stands for Environmental, Social and Governance. An ESG rating is a third-party view of how a company performs on these non-financial aspects, such as how it manages its environmental impact, how it deals with employees and the wider community, and how it governs itself. Here, Crisil ESG Ratings has assigned a score of 61 to the company, with the descriptive tag 'Strong'.
Why the company's clarification matters
The company has specifically noted that it did not engage Crisil ESG Ratings for this exercise. That means the rating was not commissioned by the company; it was prepared independently by the rating provider from publicly available data. Investors reading this update can note both the score itself and the fact that it comes from an independent assessment rather than a company-requested one.
Points to keep in mind
- This is information about the company's ESG standing, an area tracked by some institutional and ESG-focused investors alongside financial performance.
- The rating is linked to data pertaining to FY 2025-26, so it reflects that period.
- The company has stated on record that it did not engage the rating provider for this exercise.
In simple terms, the update tells investors how an external agency has scored the company on environment, social and governance parameters, and makes clear where that assessment came from.
Also from Aarti Drugs
Authorized persons for determining materiality and making disclosures to exchanges named from October 1, 2026
1 Oct 2026
Chairman, MD & CEO Prakash M. Patil retires early; Adhish P. Patil promoted to MD, steps down as CFO
30 Sep 2026
Shareholder presentation shared at 41st AGM covering FY 2025-26 milestones
26 Sep 2026
More numbers
- Crisil ESG rating assignedCrisil ESG 61
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.